Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | May 26, 2026 | May 27, 2026 |
| Presbia PLCLENS · Entity 160670 | Director · Executive Chairman | March 13, 2017 | March 22, 2017 |
| TFF Pharmaceuticals, Inc.TFFP · Entity 89110 | Director | September 29, 2022 | September 30, 2022 |
| Veradigm Inc.MDRX · Entity 13670 | Director | May 22, 2017 | May 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date May 26, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,593 |
Reported balance
After 2026-05-26 transaction · row 1
1 source rowRow 1 · 2026-05-26 · Purchase · Acquired 5,000 · Balance 5,593 |
Presbia PLC
Report date March 13, 2017 · Filed March 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 45,924 |
Reported balance
After 2017-03-13 transaction · row 1
1 source rowRow 1 · 2017-03-13 · Grant · Acquired 12,738 · Balance 45,924 F1: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Ralph H. Thurman Rev Trust | 1,833 |
Reported balance
Holding disclosure · report date 2017-03-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,833 F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018.
F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
TFF Pharmaceuticals, Inc.
Report date September 29, 2022 · Filed September 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-09-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-09-29 · Exercise / conversion · Acquired 40,255 · Balance 40,255 Row 2 · 2022-09-29 · Sale · Disposed 40,255 · Balance 0 F1: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2029-04-11 | Direct | 84,670 |
Reported balance
After 2022-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-09-29 · Exercise / conversion · Disposed 40,255 · Balance 84,670 F2: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
F2: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
Veradigm Inc.
Report date May 22, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,014 |
Reported balance
After 2017-05-22 transaction · row 1
1 source rowRow 1 · 2017-05-22 · Grant · Acquired 16,765 · Balance 105,014 F1: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2026 Filed May 27, 2026 19:20 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,000 | $0.43 | $2,145.00 |
DisclosureSEC source: 0001649989-26-000002 · primary_doc.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,593 Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 23:00 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 286,734 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001649989-25-000004 · primary_doc.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,734 Underlying: Common Stock · 286,734 shares Expires 2035-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 00:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 89,549 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024701 · form4-10032024_081001.xml · derivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,549 Underlying: Common Stock · 89,549 shares Expires 2034-10-01 F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 00:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 56,636 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024701 · form4-10032024_081001.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,636 Underlying: Common Stock · 56,636 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:04 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 94,441 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001415889-24-007319 · form4-03082024_090322.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,441 Underlying: Common Stock · 94,441 shares Expires 2034-03-07 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:44 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 41,065 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-23-021905 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,065 Underlying: Common Stock · 41,065 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 21:20 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionStock Options (Right to Buy) · Derivative | 40,255 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001213900-22-060782 · ownership.xml · derivative · entry 3 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,670 Underlying: Common Stock · 40,255 shares Expires 2029-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 21:20 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | SaleCommon Stock | 40,255 | $4.29 | $172,693.95 |
DisclosureSEC source: 0001213900-22-060782 · ownership.xml · nonDerivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F1 · price: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 21:20 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionCommon Stock | 40,255 | $2.50 | $100,637.50 |
DisclosureSEC source: 0001213900-22-060782 · ownership.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 21:36 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 81,878 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001209191-22-020949 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,878 Underlying: Common Stock · 81,878 shares Expires 2032-03-23 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:05 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | PurchaseCommon Stock | 1,050 | $9.40 | $9,870.00 |
DisclosureSEC source: 0001213900-21-027899 · ownership.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 20,873 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-21-023279 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 Underlying: Common Stock · 20,873 shares Expires 2031-03-24 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| November 13, 2020 Filed Nov 14, 2020 02:01 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | SaleCommon Stock | 5,000 | $17.17 | $85,865.00 |
DisclosureSEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 3 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 02:01 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionStock Options (Right to Buy) · Derivative | 34,504 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001213900-20-037060 · ownership.xml · derivative · entry 4 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,925 Underlying: Common Stock · 34,504 shares Expires 2029-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. F2 · derivative.exercise_date: 23,003 shares of common stock vested on April 11, 2020 and the remainder of shares scheduled to vest at an approximate rate of 5,750 every three months thereafter. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 02:01 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | SaleCommon Stock | 34,504 | $15.91 | $548,889.63 |
DisclosureSEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 02:01 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionCommon Stock | 34,504 | $2.50 | $86,260.00 |
DisclosureSEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:44 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 396,809 | $0.51 Strike: $0.71 | $203,999.51 |
DisclosureSEC source: 0001209191-20-053870 · doc4.xml · derivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,809 Underlying: Common Stock · 396,809 shares Expires 2030-10-05 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $204,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 22:44 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 259,297 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-20-053870 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,297 Underlying: Common Stock · 259,297 shares Expires 2030-10-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 22:31 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $0.62 | $6,200.00 |
DisclosureSEC source: 0001209191-20-050564 · doc4.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.62 to $0.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Reflects a 1-for-8 reverse stock split effected by the Issuer on March 15, 2019 (the "Split Date"). The Reporting Person's previous ownership of 15,000 shares of common stock was adjusted to 1,875 shares of Common Stock on the Split Date. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 22:16 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001213900-20-023901 · ownership.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,429 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021. F1 · derivative.expiration_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:11 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-043228 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| July 17, 2020 Filed Sep 17, 2020 23:20 UTC Amendment | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 154,555 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-051048 · doc4a.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,555 Underlying: Common Stock · 154,555 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 21:52 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-20-020508 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| November 29, 2019 Filed Dec 4, 2019 00:42 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 3,623 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-19-025249 · ownership.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,429 Underlying: Common Stock · 3,623 shares Expires 2029-10-29 F1 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 00:32 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 43,794 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-19-021424 · ownership.xml · derivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,806 Underlying: Common Stock · 43,794 shares Expires 2029-10-29 F2 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:32 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | PurchaseCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0001213900-19-021424 · ownership.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The shares of common stock purchased in the Issuer's initial public offering. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:08 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 207,036 | $0.99 Strike: $1.40 | $203,992.57 |
DisclosureSEC source: 0001209191-19-052709 · doc4.xml · derivative · entry 2 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,036 Underlying: Common Stock · 207,036 shares Expires 2029-10-03 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $204,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:08 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-19-052709 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 22:17 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 15,000 | $0.68 | $10,251.00 |
DisclosureSEC source: 0001209191-18-063966 · doc4.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 - $0.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:55 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 567,522 | $0.61 Strike: $0.89 | $347,890.99 |
DisclosureSEC source: 0001209191-18-058302 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,522 Underlying: Common Stock · 567,522 shares Expires 2028-11-09 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees, including Executive Chairman fee, of $348,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 21:00 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-18-052159 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 21:19 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-18-039938 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on June 27, 2021, subject to the Reporting Person providing continued service through such date. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 21:05 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-18-025216 · doc4.xml · derivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-13 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on April 13, 2021, subject to the Reporting Person providing continued service through such date. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:45 UTC | Veradigm Inc. MDRX · Entity 13670 | GrantCommon Stock | 16,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035000 · doc4.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,014 F1 · kind: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan. Read SEC document |
| March 13, 2017 Filed Mar 22, 2017 21:01 UTC | Presbia PLC LENS · Entity 160670 | GrantOrdinary Shares | 12,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-17-000378 · thurman_fm4mar132017.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,924 F1 · shares: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:05 UTC | Presbia PLC LENS · Entity 160670 | OtherSubscription Rights (right to buy) · Derivative | 16,533 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000905718-17-000331 · thurman_fm4mar102017.xml · derivative · entry 3 THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,543 shares Expires 2017-03-08 F3 · shares: Each subscription right entitled its holder to purchase 0.335297256 Ordinary Shares at a subscription price of $3.00 per whole Ordinary Share. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:05 UTC | Presbia PLC LENS · Entity 160670 | OtherOrdinary Shares | 5,543 | $3.00 | $16,629.00 |
DisclosureSEC source: 0000905718-17-000331 · thurman_fm4mar102017.xml · nonDerivative · entry 1 THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,186 F1 · shares: On March 8, 2017, the Reporting Person delivered to the Issuer an irrevocable notice of exercise of his subscription rights to purchase 5,543 Ordinary Shares, together with payment of the requisite fee, pursuant to the rights offering set forth in the Prospectus filed pursuant to Rule 424(b)(4), filed with the SEC on January 27, 2017, as amended February 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.